Cachexia

vTv Therapeutics Announces 2021 Second Quarter Financial Results and Provides Corporate Update

Retrieved on: 
Wednesday, August 4, 2021
Company, VTV, Purchasing, Chief executive officer, Program, Cachexia, RAGE (receptor), Insulin, Psoriasis, Breakthrough therapy, Patient, Diabetic ketoacidosis, Cancer, Pain, Breakthrough, Phosphodiesterase 4, Expense, Power purchase agreement, Food and Drug Administration, Risk, Regulation of tobacco by the U.S. Food and Drug Administration, Nasdaq, Research, Income, Common stock, Safety, D, Therapy, Bone metastasis, Food, GLOBE, Pharmaceutical industry, Security (finance), Aquaculture

HIGH POINT, N.C., Aug. 04, 2021 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial results for the second quarter ended June 30, 2021, and provided an update on the progress of its clinical programs.

Key Points: 
  • HIGH POINT, N.C., Aug. 04, 2021 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial results for the second quarter ended June 30, 2021, and provided an update on the progress of its clinical programs.
  • vTv expects to report topline results from this mechanistic study in late third quarter or early fourth quarter of 2021.
  • Cash Position:The Companys cash position as of June 30, 2021, was $10.8 million compared to $8.4 million as of March 31, 2021.
  • Net Loss Before Non-Controlling Interest:Net loss before non-controlling interest was$0.8 million for the second quarter of 2021 compared to net loss of$5.9 million for the first quarter of 2021.

2021 Insights on Drugs in Development for Cachexia (Musculoskeletal) - Major and Minor Projects for Key Players - ResearchAndMarkets.com

Retrieved on: 
Wednesday, July 7, 2021
Health, Pharmaceutical, Cachexia, Geriatrics, Rehabilitation medicine

The "Cachexia (Musculoskeletal) - Drugs in Development, 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cachexia (Musculoskeletal) - Drugs in Development, 2021" report has been added to ResearchAndMarkets.com's offering.
  • Additionally, the report provides an overview of key players involved in therapeutic development for Cachexia and features dormant and discontinued projects.
  • The report reviews key players involved in the development of Cachexia (Musculoskeletal) therapeutics and enlists all their major and minor projects.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Cachexia Pipeline Market Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, June 29, 2021
Health, Pharmaceutical, Medical specialties, Medicine, Clinical medicine, Cachexia, Geriatrics, Rehabilitation medicine, Pipeline, Drug pipeline

The "Cachexia - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cachexia - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • This "Cachexia - Pipeline Insight, 2021" report provides comprehensive insights about 22+ companies and 22+ pipeline drugs in Cachexia pipeline landscape.
  • This segment of the report provides insights about the different Cachexia drugs segregated based on following parameters that define the scope of the report, such as:
    There are approx.
  • Cachexia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

Cannabics Pharmaceuticals to launch Drug Development Programs for Prostate Cancer and Neurodegenerative & Mental Health Diseases

Retrieved on: 
Thursday, June 17, 2021
Clinical medicine, Medicine, Health, Antineoplastic drugs, Cancer, Treatment of cancer, Breast cancer, Chemotherapy, Cachexia

TEL AVIV, IsraelandBETHESDA,Maryland, June 17, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today the expansion of its research program with new drug development projects targeting Prostate Cancer, Neurodegenerative & Mental Health diseases.

Key Points: 
  • TEL AVIV, IsraelandBETHESDA,Maryland, June 17, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today the expansion of its research program with new drug development projects targeting Prostate Cancer, Neurodegenerative & Mental Health diseases.
  • The company plans to continue development of these drug candidates and continue testing with animal models while entering a drug regulatory development route for each indication.
  • The company has also recently announced a decision to enter the Melanoma and Breast Cancer markets with new drug development projects.
  • We now have four cancer treatment drug development projects for Colorectal Cancer (CRC), Melanoma, Breast Cancer and Prostate Cancer; one pre-cancer antitumor drug development project for the treatment of Adenomatous Polyps in collaboration with Digestix Bioscience Inc.; one palliative drug development project for the treatment of Cancer related Anorexia Cachexia Syndrome (CACS); and two early-stage drug discovery projects targeting Neurodegenerative and Mental Health diseases".

Global Cancer Cachexia Pipeline Insights Market Report 2020 Featuring AEterna Zentaris, Smartfish AS, Tetra Bio-Pharma, Pfizer, Helsinn Healthcare SA, & Lexicon Pharmaceuticals - ResearchAndMarkets.com

Retrieved on: 
Thursday, May 13, 2021
Pharmaceutical, Health, Oncology, Medical specialties, Medicine, Clinical medicine, Cachexia, Geriatrics, Rehabilitation medicine, Drug pipeline, Pipeline

b'The "Cancer Cachexia - Pipeline Insight, 2020" drug pipelines has been added to ResearchAndMarkets.com\'s offering.\nThe "Cancer Cachexia - Pipeline Insight, 2020," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Cancer Cachexia pipeline landscape.\nIt covers the pipeline drug profiles, including clinical and nonclinical stage products.

Key Points: 
  • b'The "Cancer Cachexia - Pipeline Insight, 2020" drug pipelines has been added to ResearchAndMarkets.com\'s offering.\nThe "Cancer Cachexia - Pipeline Insight, 2020," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Cancer Cachexia pipeline landscape.\nIt covers the pipeline drug profiles, including clinical and nonclinical stage products.
  • It further highlights the inactive pipeline products in this space.\nThis segment of the Cancer Cachexia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery.
  • Zentaris is conducting a pilot clinical trial of repeated doses of macimorelin to assess safety and efficacy in patients with cancer cachexia.
  • phase III and Phase II include, Tetra Bio-Pharma, Helsinn Healthcare etc.\nCancer Cachexia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

Helsinn Announces the Launch of Adlumiz® (anamorelin) for the Treatment of Cancer Cachexia in Japan

Retrieved on: 
Wednesday, April 21, 2021
Medical specialties, Clinical medicine, Medicine, Rehabilitation medicine, Cachexia, Geriatrics, Anamorelin, Cancer

This condition is a common complication of cancer, that can affect up to 80% of patients with advanced cancer.

Key Points: 
  • This condition is a common complication of cancer, that can affect up to 80% of patients with advanced cancer.
  • It has been well documented that cancer cachexia has a significant impact on patients\xe2\x80\x99 quality of life and prognosis.
  • Adlumiz\xc2\xae (anamorelin), as approved by the Japanese Health Authorities, has shown efficacy in increasing body weight, muscle mass, as well as appetite in cancer cachexia patients.
  • Helsinn operates a unique integrated licensing business model, achieving success with long-standing partners in 190 countries, who share our values.

Global Cachexia Disease Clinical Trials Review, H2 2020 Edition Featuring 10 Companies & Respective Trials - ResearchAndMarkets.com

Retrieved on: 
Wednesday, April 14, 2021
Pharmaceutical, Health, Oncology, Clinical trials, Health sciences, Health, Medicine, Pharmaceutical industry, Clinical research, Clinical trials, Drug discovery, Cachexia, Society on Sarcopenia, Cachexia and Wasting Disorders

b'The "Cachexia Disease - Global Clinical Trials Review, H2, 2020" clinical trials has been added to ResearchAndMarkets.com\'s offering.\n"Cachexia Disease - Global Clinical Trials Review, H2, 2020" provides an overview of Cachexia Clinical trials scenario.

Key Points: 
  • b'The "Cachexia Disease - Global Clinical Trials Review, H2, 2020" clinical trials has been added to ResearchAndMarkets.com\'s offering.\n"Cachexia Disease - Global Clinical Trials Review, H2, 2020" provides an overview of Cachexia Clinical trials scenario.
  • This report provides top line data relating to the clinical trials on Cachexia.\nReport includes an overview of trial numbers and their average enrollment in top countries conducted across the globe.
  • The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type.
  • Report also provides prominent drugs for in-progress trials (based on number of ongoing trials).\nReport provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status\nThe report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company\nThe report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment\nAids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials\nFacilitates clinical trial assessment of the indication on a global, regional and country level\n'

Global Cancer Anorexia-Cachexia Syndrome Disease Clinical Trials Review, H2 2020 Edition Featuring 10 Key Players & Their Respective Trials - ResearchAndMarkets.com

Retrieved on: 
Monday, April 12, 2021
General Health, Health, Pharmaceutical, Clinical trials, Oncology, Health sciences, Health, Medicine, Rehabilitation medicine, Pharmaceutical industry, Clinical pharmacology, Cachexia, Geriatrics, Clinical trial, Society on Sarcopenia, Cachexia and Wasting Disorders

b'The "Cancer Anorexia-Cachexia Syndrome Disease - Global Clinical Trials Review, H2, 2020" clinical trials has been added to ResearchAndMarkets.com\'s offering.\n"Cancer Anorexia-Cachexia Syndrome Disease - Global Clinical Trials Review, H2, 2020" provides an overview of Cancer Anorexia-Cachexia Syndrome Clinical trials scenario.\nThis report provides top line data relating to the clinical trials on Cancer Anorexia-Cachexia Syndrome.

Key Points: 
  • b'The "Cancer Anorexia-Cachexia Syndrome Disease - Global Clinical Trials Review, H2, 2020" clinical trials has been added to ResearchAndMarkets.com\'s offering.\n"Cancer Anorexia-Cachexia Syndrome Disease - Global Clinical Trials Review, H2, 2020" provides an overview of Cancer Anorexia-Cachexia Syndrome Clinical trials scenario.\nThis report provides top line data relating to the clinical trials on Cancer Anorexia-Cachexia Syndrome.
  • Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe.
  • The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type.
  • Report also provides prominent drugs for in-progress trials (based on number of ongoing trials).\nReport provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status\nThe report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company\nThe report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment\nAids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials\nFacilitates clinical trial assessment of the indication on a global, regional and country level\n'

Actimed Therapeutics and Faraday Pharmaceuticals Announce License Agreement for S-oxprenolol

Retrieved on: 
Tuesday, April 13, 2021
Branches of biology, Medical specialties, Clinical medicine, Rehabilitation medicine, Oxprenolol, Motor neuron diseases, Rare diseases, Cachexia, Muscle atrophy, Amyotrophic lateral sclerosis, Wasting

S-oxprenolol is one of a new class of anabolic-catabolic transforming agents (ACTAs) under development by Actimed.

Key Points: 
  • S-oxprenolol is one of a new class of anabolic-catabolic transforming agents (ACTAs) under development by Actimed.
  • Actimed is also eligible to receive royalties on any future sales of S-oxprenolol.
  • Faraday gains global rights to develop and commercialize S-oxprenolol for cancer cachexia and any other indications outside of amyotrophic lateral sclerosis (ALS).
  • Actimed retains global rights to S-oxprenolol in ALS, where loss of body mass and muscle wasting can impact survival.\nRobin Bhattacherjee, Actimed CEO, commented: "I am delighted with our agreement with Faraday for S-oxprenolol which is an important and mutually beneficial agreement for both companies.

Actimed Therapeutics and Faraday Pharmaceuticals Announce License Agreement for S-oxprenolol

Retrieved on: 
Tuesday, April 13, 2021
Branches of biology, Medical specialties, Clinical medicine, Rehabilitation medicine, Oxprenolol, Motor neuron diseases, Rare diseases, Cachexia, Muscle atrophy, Amyotrophic lateral sclerosis, Wasting

S-oxprenolol is one of a new class of anabolic-catabolic transforming agents (ACTAs) under development by Actimed.

Key Points: 
  • S-oxprenolol is one of a new class of anabolic-catabolic transforming agents (ACTAs) under development by Actimed.
  • Actimed is also eligible to receive royalties on any future sales of S-oxprenolol.
  • Faraday gains global rights to develop and commercialize S-oxprenolol for cancer cachexia and any other indications outside of amyotrophic lateral sclerosis (ALS).
  • Actimed retains global rights to S-oxprenolol in ALS, where loss of body mass and muscle wasting can impact survival.\nRobin Bhattacherjee, Actimed CEO, commented: "I am delighted with our agreement with Faraday for S-oxprenolol which is an important and mutually beneficial agreement for both companies.